Skip to main content

Table 3 White blood count (WBC), before sulphasalazine treatment, in subjects with or without the S173 polymorphism

From: Can mutations in ELA2, neutrophil elastase expression or differential cell toxicity explain sulphasalazine-induced agranulocytosis?

 

WBC

Subjects with S173 (n = 34)

8.74 ± 2.51

Subjects without S173 (n = 74)

8.66 ± 3.51

  1. White blood count (WBC) was estimated by the local physicians before starting with the sulphasalazine treatment. The average WBC in subjects with or without S173 is presented as the mean value ± SD. It was no statistical difference between the groups.